What is the difference between Mounjaro and Ozempic?

Mounjaro is a brand of tirzepatide, an approved dual agonist of the GIP and GLP-1 receptors. Ozempic is a brand of semaglutide, an approved single-receptor GLP-1 agonist. The mechanistic difference is that tirzepatide engages two incretin receptors and semaglutide one. Both are approved prescription medicines — this is a factual summary, not medical advice.

Do you sell Mounjaro or Ozempic?

No. Mounjaro and Ozempic are approved prescription medicines that we do not supply. They are referenced here only as the subject of published research. Elite AU Peptides supplies research-grade peptides — for the incretin-receptor space, retatrutide, tesamorelin and AOD-9604 — strictly for in-vitro and laboratory research use only.

This guide makes no comparative-efficacy or superiority claim between two approved medicines. It summarises the receptor mechanism drawn from published research. Any clinical decision about an approved medicine belongs with a qualified healthcare professional, not a research-peptide supplier.

How do these approved drugs relate to the research peptides you sell?

The approved medicines and our research peptides are studied against the same family of incretin receptors (GLP-1, GIP, and in retatrutide's case glucagon). That shared receptor biology is why the demand for information about Mounjaro and Ozempic overlaps with interest in incretin research peptides. Our compounds are supplied for laboratory research only — they are not substitutes for, or equivalents of, any approved medicine.

[ GLP-1 / incretin research ]

Mounjaro vs Ozempic: what the research actually shows

A factual, cite-don't-endorse explainer of the two approved medicines behind the mega-demand — Mounjaro (tirzepatide), a dual GIP/GLP-1 agonist, and Ozempic (semaglutide), a single-receptor GLP-1 agonist — and how they relate to the research peptides Elite AU Peptides supplies for laboratory use. Research use only.

8 min read · Updated 22 July 2026

Retatrutide research peptide vial — a GLP-1 / GIP / glucagon receptor research compound, independently HPLC-tested, COA on file

[ Research use only · Not for human consumption ]

Mounjaro vs Ozempic. Both are brand names for approved incretin-receptor medicines, and both drive enormous search interest. This guide is a factual, cite-don’t-endorse explainer of what separates them at the receptor level — and an honest note on where research peptides do, and do not, fit. Elite AU Peptides does not supply either medicine; they are referenced only as the subject of published research. Our compounds are supplied for in-vitro / laboratory research use only.

The two medicines, by mechanism

Mounjaro is a brand of tirzepatide, an approved dual agonist of the GIP and GLP-1 receptors. Ozempic is a brand of semaglutide, an approved single-receptor GLP-1 agonist. (Semaglutide is also marketed as Wegovy, and tirzepatide as Zepbound.) The mechanistic difference is straightforward: tirzepatide engages two incretin receptors and semaglutide engages one. Both are approved prescription medicines — this is a factual summary of receptor pharmacology, not medical advice or a comparison of clinical outcomes.

What the published research reports

Tirzepatide’s dual-agonist profile is documented across the SURPASS clinical-trial programme (for example, Frías and colleagues, New England Journal of Medicine, 2021). Semaglutide’s GLP-1 agonism is documented across its SUSTAIN and STEP trials. We cite these as published research findings about approved medicines — never as endorsement, and never as a claim about any product Elite AU Peptides supplies. This guide does not rank the two medicines or make any comparative-efficacy claim; that is a clinical judgement for a qualified healthcare professional.

Where research peptides fit (and where they don’t)

The reason interest in Mounjaro and Ozempic overlaps with interest in research peptides is shared receptor biology: the approved medicines and the research compounds are studied against the same incretin receptors. Retatrutide, for instance, is studied in published research as a triple GLP-1 / GIP / glucagon agonist — a research compound, supplied for laboratory use only. But shared receptor biology is not equivalence: research-grade peptides are not substitutes for, or equivalents of, any approved medicine, and are not for human use. For the receptor science in full, see the GLP-1 research peptides pillar guide; for the compound-level mechanism, the retatrutide vs tirzepatide comparison.

Identity, purity and the COA moat

The research peptides in the GLP-class & metabolic category are each independently HPLC-tested by Janoshik before listing, with the certificate published on the product page and in the lab-reports library — a real batch number, the measured percentage, and an independently verifiable report. Nothing is listed without a certificate on file.

Compliance and research-use framing

Mounjaro, Ozempic, Wegovy, Zepbound, semaglutide and tirzepatide are approved medicines that Elite AU Peptides does not supply — referenced here only as published research. The research peptides we do supply are not TGA-approved, are not therapeutic goods, and are supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption. We make no medical, therapeutic, weight-loss, or body-composition claim, and no claim that any research peptide is a substitute for an approved medicine. Anything above is a factual summary of published research, not medical advice.

[ Frequently asked ]

GLP-1 / incretin research — questions researchers ask.

What is the difference between Mounjaro and Ozempic?: Mounjaro is a brand of tirzepatide, an approved dual agonist of the GIP and GLP-1 receptors. Ozempic is a brand of semaglutide, an approved single-receptor GLP-1 agonist. The mechanistic difference is that tirzepatide engages two incretin receptors and semaglutide one. Both are approved prescription medicines — this is a factual summary, not medical advice.
Do you sell Mounjaro or Ozempic?: No. Mounjaro and Ozempic are approved prescription medicines that we do not supply. They are referenced here only as the subject of published research. Elite AU Peptides supplies research-grade peptides — for the incretin-receptor space, retatrutide, tesamorelin and AOD-9604 — strictly for in-vitro and laboratory research use only.
Which one is better?: This guide makes no comparative-efficacy or superiority claim between two approved medicines. It summarises the receptor mechanism drawn from published research. Any clinical decision about an approved medicine belongs with a qualified healthcare professional, not a research-peptide supplier.
How do these approved drugs relate to the research peptides you sell?: The approved medicines and our research peptides are studied against the same family of incretin receptors (GLP-1, GIP, and in retatrutide's case glucagon). That shared receptor biology is why the demand for information about Mounjaro and Ozempic overlaps with interest in incretin research peptides. Our compounds are supplied for laboratory research only — they are not substitutes for, or equivalents of, any approved medicine.
What published research is referenced?: Tirzepatide's dual-agonist profile is documented across the SURPASS clinical-trial programme (e.g. Frías and colleagues, New England Journal of Medicine, 2021); semaglutide's GLP-1 agonism across its SUSTAIN and STEP trials. We cite these as published research findings about approved medicines — never as endorsement.
Are the research peptides you supply TGA-approved?: No. The research peptides we supply are not TGA-approved, are not therapeutic goods, and are supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption. Every batch is independently HPLC-tested by Janoshik, with the certificate published in the lab-reports library.

[ Referenced in this guide ]

Shop the compounds

[ Keep reading ]

More research guides

Elite AU Peptides supplies research peptides and related compounds for laboratory and in-vitro research use only. Products are not therapeutic goods, are not TGA-approved, and are not for human or animal consumption. Nothing on this site constitutes medical advice or a therapeutic claim. Purchasers must be 18 years or older and are responsible for complying with all applicable laws in their jurisdiction.